The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignant tissues displayed moderate to strong membranous immunoreactivity. Malignant lymphomas, testicular cancers and stomach cancers were mainly negative.
A majority of malignancies showed moderate to strong membranous positivity.
Malignant lymphomas, melanomas, testicular and renal cancers were weakly stained or negative.
Many malignancies showed big variation in expression with negative, weak, moderate and strong samples within the same tumor type. Malignancies showed similar staining pattern as found in normal cells. Strong membranous staining found in many adenocarcinomas of e.g. colo-rectal, breast, prostate, cervix and endometrium. Gliomas were also mainly strong positive. Lymphomas, melanomas, testis and renal carcinomas were mainly negative. Cytoplasmic staining was also found in many samples but seems to be overstaining in most cases.
Validation
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
